February 22, 2021
Article
Siponimod (Mayzent; Novartis) improved Symbol Digit Modalities Test scores in patients at 12, 18, and 24 months compared to placebo.
May 27, 2020
Article
The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.
April 15, 2020
Article
The director of the Multiple Sclerosis Program at Cleveland Clinic Lou Ruvo Center for Brain Health discussed the correlation between age and disease duration in MS, as well as what was learned from a subanalysis of the EXPAND study of siponimod.
February 27, 2020
Article
Patients with a disease duration of